Press Releases

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, was recognized in last year’s annual Inc. 5000 list of fastest-growing private companies in the United States.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, attended the 2020 session of the London Maternity & Midwifery Festival in January to share the benefits SneakPeek Clinical can bring to the patients of midwifery professionals.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, has achieved a milestone of over 500 distributors of its SneakPeek Clinical test across the US and UK. Originally focusing on medical offices, the company has expanded its early gender DNA test offering to independent labs that carry a range of genetic tests.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces that the SneakPeek DNA test is now available to Australian mums to learn the gender of their babies as early as 8 weeks into pregnancy.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, reached 150,000 SneakPeek Early Gender DNA Tests sold, just five months after attaining the 100,000-test landmark in June.

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, will attend the fall 2019 session of ACOOG from October 3-6 in Columbus, OH to share the benefits SneakPeek Clinical can bring to the patients of obstetricians and gynecologists.

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the 38th annual Inc. 500|5000 list of fastest growing private companies, in the first year the company has been eligible to apply. To qualify, companies must have been founded and generating revenue by March 31, 2015. Ranking in the list is determined by the percentage revenue growth from 2015 to 2018, with minimums set for each year. With 1,786% revenue growth from 2015 to 2018, Gateway Genomics ranked #236 in the list, and #23 in the Health sector.

Gateway Genomics, a leading developer of genomic tests that give families insight into their future children, announces a new publication titled, “Accurate Fetal Sex Determination from Maternal Blood at 8 Weeks Gestation” in the International Journal of Pregnancy & Child Birth. In the study, DNA blood samples were collected from 108 women at an average gestational age of 8 weeks. Cell-free fetal DNA (cffDNA) was extracted and run through the SneakPeek test process, which looks for male chromosomes. If male chromosomes were detected in the fetal DNA found in mom’s blood, the baby was identified as male. If not, the baby was identified as female. Of 51 male-bearing pregnancies, SneakPeek correctly identified all 51, demonstrating 100% sensitivity for Y-chromosome DNA detection, even at this early stage. Of 57 female-bearing pregnancies, SneakPeek correctly identified 56, leading to a 99.1% accuracy rate for the overall study.

Gateway Genomics, leading developer of prenatal and pediatric genetic tests, announces sales of over 100,000 SneakPeek Early Gender DNA tests as of this month. SneakPeek is the first non-invasive prenatal test (NIPT) designed solely to determine fetal sex, providing an easy way for families to learn the gender of their baby as early as 9 weeks into pregnancy. The test is available through two channels: 1) An at-home version that lets consumers self-collect a DNA blood sample from the comfort of their home and mail back to SneakPeek Labs for analysis, and 2) A clinical version through participating facilities that collects the sample through a standard blood draw and sends it to SneakPeek Labs for testing. Both options can provide gender results within 1-2 days from sample collection.

Gateway Genomics, a leading developer of prenatal and pediatric genetic tests, announces an office expansion, effectively doubling its space from 2,500 to 5,000 square feet.